Share General Information
Bortezomib is the first drug of its type – a proteasome inhibitor. It is used for the treatment of multiple myeloma (MM), a blood cancer, and mantle cell lymphoma (MCL), a rare type of non-Hodgkin’s lymphoma. In MM, its use includes retreatment for patients who had previously responded to treatment with bortezomib and relapsed at least six months after completing prior bortezomib treatment.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
